Glenmark expands diabetes portfolio with new Empagliflozin treatments
Business

Glenmark expands diabetes portfolio with new Empagliflozin treatments

Glenmark Pharmaceuticals announced today the launch of Empagliflozin and its fixed-drug combinations in India under the brand names Glempa, Glempa-L, and Glempa-M. The shares of

Nasdaqpicks